Expectations of Chronic GVHD Treatment
The panel reviews recent developments in treatments, therapeutic approaches post-transplant, and the importance of clear communication in navigating patient expectations.
Source: onclive.com
Page 2 - Yi Bin Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Yi Bin Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Yi Bin Chen Today - Breaking & Trending Today
Phases of Pathophysiology of Chronic GVHD
The expert panel explores the immunological aspects of chronic GVHD, highlighting challenges in simultaneous management, addressing fibrosis, and emphasizing the importance of early intervention in evolving transplant care practices.
Source: onclive.com
ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business
/PRNewswire/ -- ImmunoFree, Inc. announced today that it has acquired all right to FCR001, a cellular therapy product, and the sponsorship of the FREEDOM-1...
Source: prnewswire.com
Diagnosis and Stratification of Acute and Chronic GVHD
Drs Yi-Bin Chen and Sophie Paczesny review the diagnosis and staging of both acute and chronic GVHD, and the challenges clinicians may encounter.
Source: onclive.com
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1
Source: businesswireindia.com